The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products

Walenga JM , Prechel MM , Jeske WP , Bakhos M. Unfractionated heparin compared with low molecular weight heparin as related to heparin-induced thrombocytopenia. Curr Opin Pulmon Med. 2005;11:385-391.

Warkentin TE , Levine MN , Hirsh J. , et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin . N Engl J Med.. 1995 ;332:1330-1335.

Amiral J. , Peynaud-Debayle E. , Wolf M. , Bridey F. , Vissac AM , Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol. 1996;52:90-95.

Bauer TL , Arepally G. , Konkle BA , et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation . 1997;95:1242-1246.

Pouplard C. , May MA , Iochmann S. , et al. Antibodies to platelet factor 4-heprin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low molecular weight heparin: clinical implications for HIT. Circulation . 1999;99:2530-2536.

Lindhoff-Last E. , Eichler P. , Stein M. , et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res. 2000;97:387-393.

Prechel M. , Bano A. , Drenth AF , Messmore HL , Walenga JM Assay selection and interpretation for laboratory testing of heparin-induced thrombocytopenia: diagnostic implications. Blood. 2001;98:36a.

Gruel Y. , Pouplard C. , Nguyen P. , et al, the French Heparin-Induced Thrombocytopenia Study Group. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol. 2003;121:786-792.

Francis JL , Palmer GP III , Moroose R. , Drexel A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg. 2003;75:17-22.

Gluckman TJ , Segal JB , Fredde NL , et al. Incidence of anti-platelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am J Cardiol. 2005;95:744-747.

Warkentin TE , Maurer BT , Aster RH Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356:2653-2654.

Ahmad S. , Untch B. , Haas S. , et al. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis . Mol Cell Biochem. 2004;258:163-170.

Ahmad S. , Haas S. , Hoppensteadt DA , et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res. 2003;108:49-55.

Ahmad S. , Bacher P. , Lassen MR , et al. Investigations of the immunoglobulin subtype transformation of antiheparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (Clivarin) in orthopedic patients. Arch Pathol Lab Med. 2003;127:584-588.

Chilver-Stainer L. , Lämmle B. , Alberio L. Titre of antiheparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems . Thromb Haemost. 2004;91:276-82.

Mattioli AV , Bonetti L. , Sternieri S. , Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J. 2000;1:39-42.

Williams RT , Damaraju LV , Mascelli MA , et al. Anti-platelet factor 4/heparin antibodies. An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation . 2003;107:2307-12

Fareed J. , Iqbal O. , Nader H. , et al. Generic low molecular weight heparins: a significant dilemma . Clin Appl Thromb Hemost. 2005;11:363-366.

Hoppensteadt D. , Jeske W. , Ahsan A. , Walenga J. , Fareed J. Biochemical and Pharmacologic Profile of Defined Molecular Weight Fractions of Heparin. Sem Throm Hemost. 1993;19:12-19.

Untch B. , Ahmad S. , Jeske W. , et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia: the pathogenic role of IgG. Thromb Res. 2002;105:117-123.

Jeske WP , Ackerman P. , Drenth A. , Walenga J. , Bakhos M. Generic versions of branded low molecular weight heparins can be differentiated in biologic and pharmacologic assays. J Thromb Haemost. 2007;5(suppl 2):P-M-647.

Izban KF , Lietz HW , Hoppensteadt DA , et al. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost. 1999;25(suppl 1):51-56.